By Brielle Benyon
The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a
… Read moreBy
A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.
Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more
The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504… Read more
A team of scientists from the Institute of Cancer Research in London has identified DNA mutations which makes cancer cells resistant to a new class of drugs called PARP inhibitors, used for the treatment of breast and ovarian cancers.
The … Read more
Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).
Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more
On August 17, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete … Read more
With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more
Maintenance treatment with olaparib (Lynparza, AstraZeneca) can significantly extend progression-free survival (PFS) in a subset of patients with ovarian cancer.
The results of a phase 3 trial showed that in patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian … Read more
Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings in the … Read more
